公开(公告)号：US20170370929A1

公开(公告)日：2017-12-28

申请号：US15535652

申请日：2015-12-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Neil T. Burford ,  Ying Han ,  Martyn N. Banks ,  Litao Zhang ,  Samuel Gerritz ,  Andrew Alt

IPC: G01N33/566 ,  A61K45/06 ,  A61K31/00

CPC classification number: G01N33/566 ,  A61K31/00 ,  A61K45/00 ,  A61K45/06 ,  G01N2333/726 ,  G01N2500/10

Abstract: Described are the discovery, synthesis and pharmacological characterization of δ-opioid receptor-selective positive allosteric modulators (δ PAMs). These δ PAMs may increase the affinity and/or efficacy of the orthosteric agonists leu-enkephalin and SNC80, as measured by β-arrestin recruitment and adenylyl cyclase inhibition. The compounds may be useful pharmacological tools to probe the molecular pharmacology of the δ receptor and to explore the therapeutic potential of δ PAMs in diseases such as chronic pain and depression.

公开(公告)号：US09655902B2

公开(公告)日：2017-05-23

申请号：US14762542

申请日：2014-01-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  Ying Han ,  Zhiwei Yin ,  Paul Michael Scola

IPC: C07D251/52 ,  C07D403/14 ,  C07D403/12 ,  A61K31/53 ,  A61P31/14 ,  A61K31/551 ,  A61K45/06

CPC classification number: A61K31/53 ,  A61K31/551 ,  A61K45/06 ,  C07D251/52 ,  C07D403/12 ,  C07D403/14

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US08722688B2

公开(公告)日：2014-05-13

申请号：US13798286

申请日：2013-03-13

Applicant: Bristol-Myers Squibb Company

Inventor： Kap-Sun Yeung ,  Kyle E. Parcella ,  John A. Bender ,  Brett R. Beno ,  Katharine A. Grant-Young ,  Ying Han ,  Piyasena Hewawasam ,  John F. Kadow ,  Andrew Nickel

IPC: A61K31/506

CPC classification number: A61K31/506 ,  A61K45/06 ,  C07D307/84 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12 ,  C07D453/00 ,  C07D491/10

Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract translation: 本公开提供式I化合物，包括其盐，以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：US20150320757A1

公开(公告)日：2015-11-12

申请号：US14762542

申请日：2014-01-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： TAO WANG ,  Zhongxing Zhang ,  Ying Han ,  Zhiwei Yin ,  Paul Michael Scola

IPC: A61K31/53 ,  C07D403/12 ,  A61K31/551 ,  C07D251/52 ,  A61K45/06

CPC classification number: A61K31/53 ,  A61K31/551 ,  A61K45/06 ,  C07D251/52 ,  C07D403/12 ,  C07D403/14

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract translation: 除了使用这些化合物的组合物和方法之外，还列举了式I化合物，包括其药学上可接受的盐。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：US20130197012A1

公开(公告)日：2013-08-01

申请号：US13798286

申请日：2013-03-13

Applicant: Bristol-Myers Squibb Company

Inventor： Kap-Sun Yeung ,  Kyle E. Parcella ,  John A. Bender ,  Brett R. Beno ,  Katharine A. Grant-Young ,  Ying Han ,  Piyasena Hewawasam ,  John F. Kadow ,  Andrew Nickel

IPC: A61K31/506 ,  A61K45/06

CPC classification number: A61K31/506 ,  A61K45/06 ,  C07D307/84 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12 ,  C07D453/00 ,  C07D491/10

Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract translation: 本公开提供式I化合物，包括其盐，以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。